A Randomized Trial Comparing The Effect Of Sacubitril/Valsartan To Valsartan On Left Ventricular Remodeling In Patients With Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction

In patients at high risk of heart failure (HF) following myocardial infarction (MI) as a result of residual left ventricular systolic dysfunction (LVSD), the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan may result in a greater attenuation of adverse LV remodeling than renin angiotensin aldosterone system inhibition alone, due to increased levels of substrates for neprilysin with vasodilatory, anti-hypertrophic, anti-fibrotic and sympatholytic effects. In a randomized, double-blinded, active-comparator trial, we examined the effect of sacubitril/valsartan compared with the angiotensin receptor blocker (ARB), valsartan, on LV remodeling in patients with asymptomatic LVSD following MI using the gold-standard method of LV assessment, cardiac magnetic resonance imaging (MRI).

Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Kieran F. Docherty, Ross T. Campbell, Katriona J.M. Brooksbank, Rosemary L. Godeseth, Paul Forsyth, Alex McConnachie, Giles Roditi, Bethany Stanley, Paul Welsh, Pardeep S. Jhund, Mark C. Petrie, John J.V. McMurray Source Type: research